Phase I/II trial of oral UFT/Leucovorin (LV) and paclitaxel (P) in the second line treatment of patients (PTS) with metastatic breast cancer (MBC)

被引：0
|
作者：
Klaassen, U [1 ]
Lang, S [1 ]
Borquez, D [1 ]
Oberhoff, C [1 ]
Benner, S [1 ]
Harstrick, A [1 ]
Seeber, S [1 ]
机构：
[1] Univ Essen Gesamthsch, W German Canc Ctr, Dept Int Med Canc Res, Essen, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81710-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1294
引用
收藏
页码：S322 / S323
页数：2
相关论文
共 50 条
  • [1] Phase I/II study of weekly paclitaxel (P), UFT and leucovorin in patients with metastatic breast cancer
    Chang, AY
    Beith, J
    Yeo, W
    Boyer, M
    Wong, J
    Lim, SE
    Chan, AT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 59S - 59S
  • [2] A phase I dose-finding trial of UFT/leucovorin (LV) in combination with vinorelbine (VNB) in patients with metastatic breast cancer (MBC).
    Fumoleau, P
    Bonneterre, J
    Kerbrat, P
    Fargeot, P
    Déporte-Féty, R
    Garet, F
    ANNALS OF ONCOLOGY, 2000, 11 : 32 - 33
  • [3] Uracil plus tegafur in a single capsule with oral leucovorin in combination with paclitaxel: A phase I/II trial as second-line treatment of patients with metastatic breast
    Klaassen, U
    Hilger, R
    Henry, J
    Benner, S
    Harstrick, A
    Seeber, S
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 12 - 12
  • [4] A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC)
    Morris, P. G.
    Abbruzzi, A.
    D'Andrea, G.
    Gilewski, T.
    Lake, D.
    Bromberg, J.
    Dang, C.
    Dickler, M.
    Modi, S.
    Seidman, A. D.
    Sklarin, N.
    Chang, J.
    Patil, S.
    Norton, L.
    Hudis, C. A.
    Fornier, M. N.
    CANCER RESEARCH, 2010, 70
  • [5] Phase II study with paclitaxel (P) and novantrone (N) as first line treatment in metastatic breast cancer (MBC).
    Fontaine, C
    Neyns, B
    Van Erps, J
    Dewaele, A
    De Grève, J
    ANNALS OF ONCOLOGY, 2000, 11 : 37 - 38
  • [6] Phase I clinical trial of bavituximab (Bavi) and paclitaxel (P) patients (pts) with HER2-negative metastatic breast cancer (MBC)
    Chalasani, Pavani
    Marron, Marilyn
    Clarke, Kathryn
    Schmidt, Kathy
    Powell, Alisa
    Iannone, Maria
    Stopeck, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients.
    Dai, Ming-Shen
    Chao, Ta-Chong
    Chiu, Chang-Fan
    Lu, Yen-Shen
    Shiah, Her-Shyongi
    Wu, Yi-Yin
    Cheng, Wei-Hong
    Chan, Wing Kai
    Hung, Tak
    Hung, Noelyn
    Cutler, David
    Kwan, Rudolf
    Kramer, Douglas
    Chao, Tsu-Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC)
    Jhaveri, K.
    Chandarlapaty, S.
    Lake, D.
    Gilewski, T.
    Drullinsky, P.
    Sugarman, S.
    Wasserheit-Leiblich, C.
    Moynahan, M. E.
    D'Andrea, G.
    Haque, S.
    Patil, S.
    Bauman, L.
    Vukovic, V.
    El-Hariry, I.
    Hudis, C.
    Modi, S.
    CANCER RESEARCH, 2011, 71
  • [9] A phase I/II study of tegafur-uracil (UFT) plus oral leucovorin (LV) and biweekly CPT-11 therapy for patients (pts) with metastatic colorectal cancer (CRC).
    Uetake, H
    Tetsuro, H
    Enomoto, M
    Sugihara, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 303S - 303S
  • [10] Paclitaxel, uracil plus tegafur (UFT) and leucovorin (LV) in patients with pre-treated metastatic breast cancer: Preclinical rationale and phase I study results
    Passardi, A.
    Massa, I.
    Milandri, C.
    Cecconetto, L.
    Calpona, S.
    Ibrahim, T.
    Ridolfi, L.
    Zoli, W.
    Frassineti, L.
    Maltoni, R.
    ANNALS OF ONCOLOGY, 2006, 17 : XI11 - XI12
12345